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Abstract
Hydrocephalus 2008 was held 17–20 September in Hannover, Germany, at the invitation of Petra
M Klinge (President), co-hosted by Joachim K. Krauss (Vice President), and Madjid Samii (Honorary
President). This meeting was a successor to Hydrocephalus 2006 held in Göteborg, Sweden,
organised by Past-President, Carsten Wikkelso. The conference began with a general introductory
session of six talks including three invited lectures, followed by eighteen parallel sessions. Subjects
covered were hydrocephalus signs, symptoms and diagnosis, especially in normal pressure
hydrocephalus; cerebrospinal fluid (CSF) physics and dynamics; CSF function and modelling of
function; dementia and quality of life, economy, health care and rehabilitation; neuropsychology,
cognition and outcome assessment; neuroimaging, functional imaging and non-invasive diagnostics;
paediatric and adolescent hydrocephalus; intelligent shunt and valve design (e.g. telemetry,
adjustable and antimicrobial shunts); endoscopic third ventriculostomy; technical advances and
image-guided surgical approaches in the treatment of hydrocephalus; brain metabolism, biomarkers
and biophysics; co-morbidity, classification and aetiology; epidemiology, registries and clinical trials;
experimental hydrocephalus; and pharmaceutical modulation of central nervous system function
(CNS drug delivery). Each session began with introductory talks from the invited chairpersons
followed by six to eight submitted oral presentations. Overall, 136 oral presentations and 18
posters were presented, the abstracts of which were published elsewhere [1]. We present here an
account of the introductory session, the invited chairperson's talks and the concluding remarks by
Anthony Marmarou.
Introduction to Hydrocephalus 2008
Welcome to Hannover, welcome to 'Hydrocephalus 2008'.
Madjid Samii
Madjid Samii as Honorary President, welcomed partici-
pants to Hannover for Hydrocephalus 2008, in particular
Tony Marmarou, a pioneer and leader in the field for
hydrocephalus research for over 30 years, and Peter Black
as Guest of Honour and President-Elect of the World Fed-
eration of Neurosurgical Societies. He thanked Carsten
Wikkelso for organising the previous meeting in 2006,
and for having Petra Klinge host Hydrocephalus 2008.
Hydrocephalus is a problem that neurosurgeons face
every day and the onset of hydrocephalus with an increase
in intracranial pressure is a permanent sequel to neurosur-
gery. Neurosurgeons need to understand the variable
pathophysiology of hydrocephalus and at the same time
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to search for the best treatment option. Hydrocephalus
has many causes, some not fully understood, and neuro-
surgeons puzzle over why only some patients develop
hydrocephalus, the poorly-understood pathology, and
why these patients react so differently to treatment. The
objective for this meeting was to provide a forum for eval-
uating experiences, and for solving ongoing problems for
patients.
Introduction to the meeting report on Hydrocephalus 2008.
Petra M. Klinge, President of Hydrocephalus 2008.
After the success of the first multi-/interdisciplinary inter-
national conference in Göteborg, this second conference
was planned to take place in Hannover, Germany, in Sep-
tember 2008. The format introduced at Hydrocephalus
2006 was adopted in 2008, in that the session chairs pre-
sented introductory state-of-the-art lectures, together with
recommendations for future directions.
Hydrocephalus 2008 aimed to cover both the traditional
(established), as well as the more non-traditional con-
cepts of hydrocephalus research. Traditionally, hydro-
cephalus has been approached through an understanding
of fundamental changes in the brain and the cerebrospi-
nal fluid (CSF) physics and dynamics. Both clinical and
experimental research on brain metabolism and chemis-
try and on aspects of brain function and functional out-
come, promise a better insight into the disease. However,
these aspects have not been emphasised at scientific con-
ferences and as yet, have not been used in clinical decision
making for shunt treatment, for novel treatment options,
or outcome assessment of hydrocephalus.
Cognition and the life-time cognitive deficit in hydro-
cephalus are increasingly recognized as a paramount bur-
den to patients that impact on the results of shunt
treatment. As such, clinicians have to understand cogni-
tive domains and cognitive function in hydrocephalus,
neuropsychological assessment and aspects of neuroreha-
bilitative treatment. This calls for inter-disciplinary and
multidisciplinary cooperation and a disease approach, as
for example, in the dementia and co-morbidity of demen-
tia in idiopathic normal pressure hydrocephalus (NPH).
It is now understood that so far, the shunt has not
resolved all aspects of the disease, and maintaining
favourable long term outcome in patients is constrained
by various technical and physiological obstacles. The use
of pressure-adjustable valves, novel approaches in shunt
and valve design and invasive measures to approach dis-
ease mechanisms, are promising. It requires physicians,
researchers, engineers, the medical industry and manufac-
turers to establish mutual exchanges of basic scientific
knowledge, experience and scientific achievements. Fur-
thermore, indications for endoscopic third ventriculos-
tomy (ETV) are currently expanding. ETV is increasingly
used as the first-choice-treatment instead of shunt treat-
ment in both communicating and non-communicating
hydrocephalus because it may provide a physiological res-
toration of CSF pathways and CSF dynamics.
Universal guidelines in hydrocephalus have been absent
through a lack of prospective and standardized trials to
support recommendations for standards of care. As a con-
sequence, prospective multicenter trials involving stand-
ardized reporting of diagnosis, treatment and outcome in
a larger number of patients are evolving around the world.
Also, and probably a point of utmost concern, attempts at
a better classification scheme have been put forward. Con-
sequently, topics were chosen for this conference based on
the above issues, hoping to stimulate new facts and novel
interpretations. Novel aspects were sessions dedicated to
research in experimental hydrocephalus and to pharma-
ceutical modulation of the CNS (CNS drug delivery), in
order to underline and pursue the translational aspect of
hydrocephalus research. For example, recent research
findings on neuromodulation in neurodegenerative dis-
eases will eventually translate into an adjunct treatment
arm for hydrocephalus in the future.
Accordingly, the conference succeeded in recruiting an
inter- and trans-disciplinary team of experts, speakers and
chairs, coming from the various professions and groups
involved in the treatment and care of patients with both
paediatric and adult hydrocephalus and dementia and
involved in neurological research [see additional file 1].
The focussed talks from the session chairs, plus the lec-
tures in the opening and closing sessions of the confer-
ence, are summarized in this report.
Introductory session
Paradigm shifts among a multitude of axes – Hydrocephalus
2008. Joachim K. Krauss
There have been several meetings worldwide, focussed on
hydrocephalus, just to mention the last one, the Interna-
tional Hydrocephalus Workshop 2007, organized by
Anthony Marmarou in Rhodes in 2007. When hydroceph-
alus is discussed, many different aspects of neurosurgery
and neurology are included. However, when we look back
in history, only 50 years ago hydrocephalus was a histori-
cal curiosity. Normal pressure hydrocephalus (NPH) was
discovered only 40 years ago. Even now, the whole picture
is not yet clear and it is necessary to raise awareness of
hydrocephalus. Hydrocephalus may be the most common
disorder treated worldwide, it creates a major burden of
suffering and there are many humans with shunts all
around the world.Cerebrospinal Fluid Research 2008, 5:19 http://www.cerebrospinalfluidresearch.com/content/5/1/19
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Journals and newspapers need to draw attention to the
disease. For example, recently the journal Focus  had a
unique article stating 'It was the hydrocephalus' about a
patient long suffering from NPH and facing various obsta-
cles before being adequately diagnosed and treated. The
patient is now back to his previous life and enjoying his
motorbike. It is hoped that by increasing public awareness
of the potential for a cure, patients can be treated earlier
and more efficiently. According to a survey on practition-
ers in North America, published by Dr. H. Conn, an emer-
itus physician from Yale University and suffering from
normal pressure hydrocephalus (NPH), one third of the
physicians had never heard about this condition. Even
among specialists, knowledge is poor regarding the appro-
priate diagnosis of NPH. A survey in neurosurgical centres
in Germany in 1999 showed that most centres obtained
CSF tap test volumes anywhere between 0 and 20 ml.
Also, there was no consensus for cut-off limits for CSF tap
test or for CSF B-wave frequency and amplitude. So there
an urgent need to come to an agreement regarding what
we think hydrocephalus is and what it is not.
Paradigm shifts have occurred in hydrocephalus, e.g., the
concept of longstanding overt ventriculomegaly (LOVA),
which gives entirely new perspectives for treatment. Also
we understand that NPH is not only a disorder of CSF
dynamics, but is also a disorder of the brain. Finally,
progress has been made with endoscopic third ventricu-
lostomy (ETV) with more indications and potential and
there has been considerable improvement in shunt tech-
nology in the past five years. To summarize, in the 60s and
70s we had the period of optimism, in the 80s and 90s
there was period of nihilism, and now have to come to the
period of realism and we have to see what will be in 10
years from now. There are a lot of 'hidden traces' and 'lost
highways' in hydrocephalus, however, both, the more
attractive and the less attractive topics are circulating at
conferences, and it is hoped that we are able to create a
balance between all important relevant topics helping to
improve interdisciplinary hydrocephalus research.
Challenges in hydrocephalus Research. Carsten Wikkelso
Traditionally, hydrocephalus has been the 'Aschenputtel'
or Cinderella, of both neurosurgery and neurology. To
overcome this and establish a solid ground for developing
the care of patients with hydrocephalus we must concen-
trate on remaining challenges in hydrocephalus research.
First of all we should come to an agreement on definitions
for the disorder (hydrocephalus) and the specific causa-
tive or idiopathic diseases with hydrocephalus like steno-
sis of the aqueduct. The treatment of children and young
adults with so-called arrested or asymptomatic hydro-
cephalus is a controversial subject. We need to answer
whether these individuals are harmed more by living with
an enlarged ventricular system than by being shunted.
Past studies have indicated that shunt treatment improved
children and young adults with arrested and asympto-
matic hydrocephalus.
The most important challenge for the hydrocephalus
community is probably to establish a common scale for
evaluation of symptoms and signs. To agree on a common
scale is a basic requirement for interpretation of symp-
toms and signs and improvement after surgery reported in
different studies. Such a scale should contain continuous
variables and high validity, reliability, sensitivity, ability
to detect changes, appropriateness, feasibility and inter-
pretability. At the moment we are operating on only 20 to
25% of the patients with idiopathic normal pressure
hydrocephalus (iNPH) according to recent studies of
prevalence and incidence. Why is that? One reason might
be lack of awareness among physicians. Another reason
might be that the symptoms often resemble those of
other, not yet treatable, brain disorders such as Bin-
swanger's disease, a small vessel disease affecting mainly
periventricular white matter. A third reason might be that
the available diagnostic tools have limited sensitivity and
specificity and poorly predict postoperative outcome, and
fourthly the surgery is relatively minor but has the poten-
tial for many complications.
Concerning symptoms and signs, we have made improve-
ments and iNPH is no longer just the triad but a syndrome
characterised besides gait, mental and bladder symptoms,
by interrelated postural dysfunction and other motor
impairments. The gait disturbance in iNPH has been fur-
ther characterised clinically and neurophysiologically as
reduced gait velocity, broad based, diminished stride
length, reduced foot to floor clearance, increased foot
angle and freezing of gait. An important feature requiring
further evaluation is characteristic retropulsion, which
explains up to one third of gait and balance problems. A
number of recent studies on the neuropsychological pro-
file of iNPH have revealed important results. All tested
domains that were impaired in iNPH patients, improved
after shunt surgery, inversely in relation to the degree of
prior impairment. Enhancing the sensitivity, specificity
and predictive values of the available diagnostic tools are
ongoing studies. The best predictive test is probably the
external lumbar drainage test, but even so, up to 20% of
patients who would be excluded from shunt surgery by
that test, would improve with surgery.
Disturbed CSF dynamics induce metabolic and degenera-
tive changes in the periventricular brain tissue. It is well
known that cerebral blood flow (CBF) is reduced globally,
and regional reductions have been reported in frontal
lobes and hippocampus, thalamus and basal ganglia and
periventricularly. Oxygen metabolism is reduced in theCerebrospinal Fluid Research 2008, 5:19 http://www.cerebrospinalfluidresearch.com/content/5/1/19
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basal ganglia and periventricular regions; in most cases
above penumbra level with intact auto-regulation. CSF
biomarkers have shown interesting changes in iNPH. CSF
TNF-α (a pro-inflammatory cytokine involved in apopto-
sis and toxic to oligodendrocytes) is very high before sur-
gery and normal after surgery indicating that the altered
CSF dynamics radically changed the inflammatory state.
Neurofilament protein an axonal marker has been
reported as increased in several studies, indicating dys-
function or damage to the axons. Sulfatide, a marker of
demyelinisation, has been reported increased in patients
with Binswanger's disease but normal in NPH patients,
potentially making it a good differentiating marker. The
water content measured as apparent diffusion coefficient
or fractional anisotropy is high in the periventricular tis-
sue in acute hydrocephalus but normal in chronic or NPH
patients. Magnetic resonance imaging (MRI) is a promis-
ing technique with many methodological opportunities.
International co-ordination of protocols might be impor-
tant for establishing methods for visualising cortical and
periventricular diffusion, perfusion, metabolic state and
reversibility.
Idiopathic normal pressure hydrocephalus (iNPH) versus long-
standing overt ventriculomegaly in adults (LOVA) – Current
Status and Modern Concept of Adult Hydrocephalus. Shizuo
Oi
Twenty five years after Hakim and Adams introduced the
term normal pressure hydrocephalus, the unique concept
of LOVA was introduced. Although the clinical picture has
similarities with NPH, the aetiological and pathophysio-
logical aspects are different. LOVA is an infant-type hydro-
cephalus with severe ventriculomegaly and asymptomatic
except for headache and macrocephaly, but which turns to
high pressure symptomatic hydrocephalus in adulthood.
In the first series of 16 cases reported, headache was
present in 15, but also gait disturbance was seen in 12,
dementia in 11 and urinary incontinence in 8 patients.
Patients had aqueductal stenosis; hence LOVA is a non-
communicating hydrocephalus. New concepts in the def-
inition of adult-type hydrocephalus are needed. The defi-
nition of NPH has always created confusion and
controversy. The triad (gait, mental and bladder symp-
toms) has never been specific to iNPH but can occur in
any type of adult hydrocephalus. Also, the intracranial
pressure (ICP) dynamics are not always within the normal
range and iNPH can be confused with high pressure
hydrocephalus. In some iNPH patients, CSF dynamic tests
and imaging may show that the hydrocephalus is not truly
communicating.
Based on the experiences with LOVA, hydrocephalus
should be clearly defined from the changes over time and
not purely on a one-time ICP dynamic study. Although all
types of adult hydrocephalus, both secondary and idio-
pathic, start with high pressure in the acute phase, they
may change in the chronic state, exhibiting a normal
range of ICP and normal dynamics, independent of the
cause and site of obstruction. In the intermediate-term, or
during disease progression, they may have variable base-
line pressures with or without wave-like elevations. Dur-
ing this chronological continuum, some patients present
with progressive hydrocephalus, and hydrocephalic
dementia (HD) is one prominent symptom.
Probably, only a small group of adults with hydrocepha-
lus have true NPH, as defined by normal baseline ICP,
clinical symptoms that may or may not exhibit the ele-
ments of the triad, and CT/MRI exhibiting ventriculomeg-
aly with obliterated cortical sulci. In a series of
hydrocephalic adults, we found 20 LOVA, 13 HD and 3
true NPH patients. Ventriculo-Cisternography is recom-
mended as an important diagnostic element in adult-type
hydrocephalus as it identifies the regular CSF pathway
and may reliably confirm aqueductal stenosis.
In appreciation of Dandy's pioneering work on classifica-
tion of hydrocephalus, we must distinguish between
obstructive and non-communicating hydrocephalus
because obstructions can occur anywhere along the path-
way of CSF flow. Probably the only true non-obstructive
types of hydrocephalus are venous sinus thrombosis, and
choroid plexus papilloma leading to CSF overproduction.
Any attempt at a better classification should consider
onset, causes, underlying lesions, symptoms, CSF circula-
tion and ICP dynamics, changes over time and post-shunt
or ETV response. Certainly, therapeutic specificity should
be emphasized since the various responses to shunt treat-
ment or CSF drainage can only be explained by individual
variations in the capacity for CSF production and absorp-
tion. Some patients with true NPH are only treatable with
low-pressure shunts or an extremely low-pressure valve
system. As such, shunt treatment response depends on
each individual's capacity for CSF production and absorp-
tion. LOVA is treated with third ventriculostomy, how-
ever, with severe ventriculomegaly and a thinned cortical
mantle, it needs a delicate endoscopic technique with
freehand manoeuvres to control actions and fine instru-
ments. LOVA is probably the most mysterious observa-
tion in hydrocephalus since we still do not understand,
why severe but asymptomatic ventriculomegaly in a 14
year old girl with a verbal IQ of 150, can turn into symp-
tomatic hydrocephalus in late life.
Future of academic neurosurgery and the future of hydroceph-
alus. Peter M Black
Neurosurgery is an important discipline in hydrocephalus
management, and therefore its future may have importantCerebrospinal Fluid Research 2008, 5:19 http://www.cerebrospinalfluidresearch.com/content/5/1/19
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implications for hydrocephalus. This report outlines three
important elements of academic neurosurgery–interdisci-
plinary work, innovation, and international relationships
and comments briefly on their relation to the hydroceph-
alus initiative represented at this meeting.
Most advances in science and clinical care are now being
made through interdisciplinary cooperation. Neurolo-
gists, neurosurgeons, nurses, physical therapists, basic sci-
entists, engineers, and other medical specialists are all
involved in hydrocephalus and their voices should all be
heard as we move forward in this field. In the future, the
leader who can mobilize and coordinate multidiscipli-
nary groups is most likely to achieve major advances both
in clinical and research work in hydrocephalus. Examples
of such leadership exist in the 52 year-old Society for
Research into Hydrocephalus and Spina Bifida and the
newly-formed International Society for Hydrocephalus
and CSF Disorders.
Innovation is a second critical component of academic
neurosurgery in relation to hydrocephalus. Harvey Cush-
ing's 1925 book The Third Circulation and its Channels was
an example of the importance of this area in neurosurgery.
Lewis Weed in Cushing's laboratory at Harvard made
major contributions to this field. His work led to two dif-
ferent approaches to CSF physiology at Harvard that were
championed by Edgar Bering involving pulsations, and
the steady-state analyses of John Pappenheimer. The
innovative work of Holter and others led to reliable valve
technology. In the 1980's, Carlos Hakim working in our
CSF laboratory developed the concept of a programmable
valve which has dramatically changed shunt design. Basic
physiology, engineering, imaging, and clinical trials are all
important areas for innovation in neurosurgery and espe-
cially in hydrocephalus.
Finally, international initiatives are critical in the future of
neurosurgery and hydrocephalus. The Society for
Research into Hydrocephalus and Spina Bifida and the
new International Hydrocephalus Society are groups
which exemplify the union of many countries in pursuing
a particular problem. The World Federation of Neurosur-
gical Societies, which represents 110 neurosurgical socie-
ties around the world and provides instruments and
training to neurosurgeons in developing countries, is
another example of globalism in neurosurgery. The prob-
lems of hydrocephalus, of deciding whether third ven-
triculostomy or shunt placement is the best approach, of
developing inexpensive shunts, and of assessing our man-
agement of hydrocephalus in paediatric and adult life, is a
great example of the importance of international initia-
tives in the present world.
Interdisciplinary efforts, a focus on innovation, and
emphasis on international collaboration are three of the
most important elements of academic neurosurgery and
academic medicine in general. Hydrocephalus and the
meetings that bring scientists and clinicians working on it
together are prime examples of these elements.
Hydrocephalus – signs and symptoms
The gait disorder of normal pressure hydrocephalus. Henning
Stolze
The gait disorder of NPH is typically hypokinetic with a
reduced velocity due to short and shuffling steps. It is not
correct to describe the gait pattern of NPH as ataxic, since
ataxia is a typical symptom of a disordered cerebellum. It
has been also described as the plate iron gait, since the feet
are not raised high enough during the swing phase and are
shuffled over the ground. Gait and balance should always
be investigated together, since balance is also severely
affected in NPH, patients often having a positive history
of falls. The pull test, according to the investigation of Par-
kinson's disease (PD) patients, is mostly abnormal.
Our quantitative investigations, which compared gait in
NPH and PD patients, have shown that the most distinc-
tive parameters for differentiation between these disor-
ders are the balance-related gait parameters. In NPH, the
step width is enlarged to a broad-based gait pattern. Also
the foot angles are abnormal with the feet rotated out-
wards on the ground. This shows there is an increased
need for stability in NPH. Further, PD patients walk with
a reduced arm swing compared to NPH. Here arm swing
is often exaggerated, so that NPH patients look as though
they are propelling themselves forward. However, it is
quite difficult to differentiate NPH patients from the gait
pattern in microvascular disease (subcortical arterioscle-
rotic encephalopathy). Here it is helpful to look for asym-
metry due to slight hemiparesis.
Summary of session on hydrocephalus signs and symptoms.
Carsten Wikkelso, (speaking in place of John Pickard)
The papers in this session showed the interrelation
between various elements of the symptoms and signs in
chronic hydrocephalus; motor, mental and other physical
signs. Only formal and standardized assessment and
standardized protocols in conjunction with the diagnostic
tests, e.g., before and after TAP-test or drainage, or before
and after treatment, allow interpretation and understand-
ing of how and which of the symptoms and signs of
improvement after surgery, are related to the disease.
Modelling and physics of hydrocephalus
Anatomy and biomechanics in hydrocephalus. Michael KieferCerebrospinal Fluid Research 2008, 5:19 http://www.cerebrospinalfluidresearch.com/content/5/1/19
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Anatomical aspects can explain most clinical signs of
hydrocephalus. These are the predisposed sites for ven-
tricular enlargement (e.g. frontal lobes), the long periven-
tricular course of lower limb pyramidal fibres and
midbrain structures. Simple physical laws (LaPlace, Pas-
cal) are fundamental for the understanding of hydroceph-
alus pathophysiology. Recently, traditional
pathophysiology has been challenged because elevated
resistance to outflow (Rout) and trans- or intra-mantle
pressure gradients have been shown to be inessential for
disease progression. Furthermore, transmantle pressure
gradients are also absent in non-communicating hydro-
cephalus.
Apparently, the starting point of hydrocephalus evolution
is reduced arterial and/or cranio-spinal compliance hin-
dering the physiological Windkessel effect of the basal
arteries, which increases capillary pressure and reduces
cerebral blood flow. Both together reduce cerebrospinal
fluid (CSF) absorption and elevate Rout  accordingly.
Higher capillary pressure results in pronounced brain pul-
sations which hit incompressible water (CSF) at the inner
and outer surfaces. The consequences of Pascal's law and
variations in local parenchymal compliance, due to differ-
ences between intracranial and venous pressures (Starling
mechanism) result in pronounced periventricular destruc-
tion. The outer brain is less affected due to greater damp-
ing (compliance). Thus isolated ventricular widening
despite free communication between the CSF spaces
occurs on the basis of reduced compliance and the Wind-
kessel effect. This also explains the close link between
hydrocephalus and cerebrovascular diseases.
The impact of modelling on the 'Renaissance' of intracranial
hydrodynamics: James P. (Pat) McAllister II
The presentations in this session demonstrate the impres-
sive progress that has been made in the last two years in
the area of modelling the hydrodynamic effects of hydro-
cephalus, especially in the area of intracranial pulsatility.
While these advances are shedding new light on the asso-
ciation between intracranial pulsatility and hydrocepha-
lus, the cause and effect relationships still are not known.
It is quite likely that abnormal pulsatility may impair cer-
ebrovascular function, and technical advances have made
it possible to quantify specific changes in parenchymal
capillary pulsatility. Future studies should reveal the cellu-
lar nature of these changes, now that a few reports have
shown that shear forces can cause endothelial cell dys-
function. Nevertheless, it is important to keep in mind
that the hydrocephalic brain is much more than a homo-
geneous 'sponge', with gliosis, inflammation, and micro-
vessel morphology playing important roles. Sophisticated
approaches now allow measurement of the viscoelastic
properties of the hydrocephalic brain and these properties
will soon be evaluated in vivo. Finally, the roles that cellu-
lar plasticity and physiological compensation play in pro-
gressive hydrocephalus, especially in maturing and aging
brains, must be incorporated into our knowledge of the
pathophysiology and clinical symptoms of this disorder.
Neuroimaging
Neuroimaging in normal pressure hydrocephalus: In search of
a diagnostic imaging sign – what did we learn so far? Mats
Tullberg
The history of neuroimaging in normal pressure hydro-
cephalus (NPH) embraces more than three decades. A
number of imaging modalities have been used to study
anatomy as well as function. While we are still waiting for
a major diagnostic breakthrough, recent studies have
above all helped us improve our understanding of NPH
pathophysiology. Certain anatomical changes are seen in
NPH, such as flattening of cortical sulci, widening of tem-
poral horns, a dilated third ventricle, enlarged Sylvian fis-
sures, focally dilated sulci and an increased flow void
signal in the aqueduct. None of these signs have proved
reliable as diagnostic markers – their presence merely sup-
ports the diagnosis. Vascular changes are frequent in the
white matter. Other possible white matter changes are
chronic ischemia, neuronal dysfunction, loss of white
matter integrity and increased water content. Some imag-
ing studies claim to measure viability of neurons. There is
evidence of a potentially reversible metabolic disturbance
in NPH, affecting different regions such as frontal, parietal
and temporal cortex, hippocampi, white matter, mesen-
cephalon, the basal ganglia and thalamus.
A major problem is the large diversity in NPH neuroimag-
ing. Study aims differ, patient groups are often small and
the results often contradictory. A task force should be
formed to identify the most important issues to solve and
urge imaging centres to perform joint studies, thereby
gathering large patient samples, using the same diagnostic
criteria and evaluation methods.
Neuroimaging of hydrocephalus: future directions. Norman
Relkin
Neuroimaging plays an important role in the clinical
management of hydrocephalus and will likely contribute
even more in the future. Quantitative analysis can be used
to extract more information from brain images than sim-
ple visual inspection allows. Available techniques permit
accurate measurements of brain and ventricular volumes
from isotropically acquired magnetic resonance images
(MRIs). Serial volumetric measurements may help differ-
entiate ventricular enlargement in hydrocephalus from
brain atrophy and more sensitively assess shunt response.Cerebrospinal Fluid Research 2008, 5:19 http://www.cerebrospinalfluidresearch.com/content/5/1/19
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There are many types of structural, functional and molec-
ular images that can now be used to map the microscopic
integrity, physiology and biochemistry of the brain in
hydrocephalus. Diffusion tensor methods permit non-
invasive examination of microscopic tissue properties
such as diffusivity, anisotropy and tractography. Phase
contrast techniques allow quantification of flow in the
vascular and cerebrospinal fluid compartments. Func-
tional and molecular imaging methods are also undergo-
ing explosive development and may prove most useful in
the differential diagnosis of conditions that mimic or co-
exist with hydrocephalus.
To translate these advances in neuroimaging into clinical
practice, normative and disease databases must be created
using standardized data acquisition and analysis methods
that are optimized for hydrocephalus. This task could be
expedited by the creation of an international hydrocepha-
lus neuroimaging consortium that assists in multicenter
studies and shares methodology as well as imaging data
between sites.
Aspects of CSF and blood flow dynamics and 
pathology in hydrocephalus
Vascular components of CSF dynamics – an update. Zofia
Czosnyka
Starting from mid 1980's, many brain imaging studies
were focussed on altered cerebral blood flow and its dis-
tribution in patients suffering from normal pressure
hydrocephalus (NPH). In experimental studies we find
evidence that both hypercapnia and hypotension affect
resistance to CSF outflow (Rout), although not very
strongly. Hypercapnia increases Rout  and hypotension
decreases Rout. From clinical practice, we know that intrac-
ranial pressure (ICP) B waves which are helpful in the
diagnosis of NPH, are probably caused by similar fluctua-
tions in cerebral blood flow detectable by transcranial
Doppler (TCD). Waves of the same frequency as ICP B
waves can be also seen in cerebral blood oxygenation
monitored with near infrared spectroscopy. Similarly, pla-
teau waves of ICP, are provoked by intrinsic increase in
cerebral blood volume, due to vasodilatation. In idio-
pathic intracranial hypertension there is a strong link
between ICP and sagittal sinus pressure. A rise in ICP pro-
voked by lumbar infusion produces an equivalent rise in
sagittal sinus pressure. This is probably due to pressure on
the dural sinuses by rising ICP and results in obstruction
of venous blood outflow. Pressure reactivity, calculated
from variations between arterial pressure and ICP is corre-
lated positively with Rout. Surprisingly, the character of
this relationship reverses after shunting. There is enough
evidence that testing CSF dynamics should be supple-
mented by testing the cerebrovascular reserve- using for
example, non-invasive CO2 reactivity or modern brain
imaging techniques. In NPH, CBF in white matter
decreases as a function of distance from the surface of ven-
tricles. In normal volunteers the distribution of CBF is flat.
Autoregulation is less efficient closer to surface of ventri-
cles than further away from ventricles. If cerebrovascular
defects are severe, no matter how disturbed the CSF circu-
lation, the shunt is unlikely to help.
In conclusion, CSF dynamics and CBF regulation are
strongly coupled. The problem is that in pathophysiology
of hydrocephalus we still do not know what is a chicken
and what is an egg.
CSF dynamics in the macro and micro environment. Martin
Schuhmann
The bulk flow concept of CSF dynamics has failed to
explain other forms of hydrocephalus than that caused by
obstruction of the intraventricular CSF pathways or the
ventricular outflow. The hydrodynamic hypothesis for
hydrocephalus considers in addition to a pure bulk flow
problem, the dynamic pulsatile nature of the CSF move-
ment in concert with the venous and arterial pulsatility
and the pulsatile movement of the brain itself. Further-
more, the CSF reabsorptive capacity is considered to be per
se unlimited. CSF reabsorption most likely occurs together
with the hundred fold amounts of arterially filtered extra-
cellular fluid, into the venous side of the capillary bed.
The hydrodynamic viewpoint can explain how, apart
from the intraventricular interruption of the CSF bulk
flow, an obstruction of the intraventricular and extraven-
tricular CSF spaces changes local and global compliance
and in consequence, pulsatility patterns, which leads to a
hydrocephalic condition. The experimental McAllister
model of basal cistern obstruction supports this by creat-
ing severe hydrocephalus simply by changing the basal
cistern properties. In clinical practice therefore diagnostic
methods like high resolution MRI for anatomical evalua-
tion of the CSF spaces, multidirectional CSF flow studies
for functional analysis, and computerised ICP analysis of
pulsatility and compliance, need to be combined to
develop an overall understanding of the underlying
pathology in individual patients.
Assessment of CSF dynamics for diagnosing 
hydrocephalus
Anders Eklund and Nina Andersson
Shunt insertion explicitly changes the CSF dynamics in
patients with hydrocephalus, causing many to improve
clinically. However, the relationship between a changed
hydrodynamic state and improved clinical performance is
not fully known. Therefore, further research in this area is
an important challenge for the hydrocephalus research
community. This work involves development of betterCerebrospinal Fluid Research 2008, 5:19 http://www.cerebrospinalfluidresearch.com/content/5/1/19
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methods for assessment of CSF dynamic parameters as
well as studies to test hypotheses on relationships
between CSF dynamics and outcome after shunting. The
aims are for a better understanding of hydrocephalus
pathophysiology and to find new predictive tests.
The model of the CSF dynamic system includes a pressure-
independent outflow resistance (Rout), pressure-depend-
ent total craniospinal compliance and a constant CSF for-
mation rate. The pulsatile properties are further described
by the relationship between cardiac-related arterial expan-
sion together with venous, intracranial and spinal com-
pensatory properties.
The most basic CSF dynamic measurement is intracranial
pressure (ICP). From this record not only can the mean
ICP be determined, but physiological variations such as B-
waves, respiratory waves and ICP pulsations can also be
analysed. Recently, there has been a number of studies
suggesting that a large cardiac pulsatility in the pressure
recording is a good predictor for a positive outcome from
shunting, and also that the pulse amplitude is reduced by
shunting. This indicates that hydrocephalus patients have
a decreased compliance, possibly due to a slightly
increased ICP. After shunting, ICP is reduced giving a bet-
ter compensatory ability. This also creates a link between
the bulk flow theory and the pulsatility phenomenon.
Cardiac-related CSF and blood flow measured with phase
contrast MRI are another possibility for assessment of CSF
dynamics. Increased CSF pulsatility in the aqueduct is sug-
gested as an indication for idiopathic normal pressure
hydrocephalus (iNPH). Another iNPH-related assessment
is a shorter arterial venous time delay between blood flow
in carotid arteries and sagittal sinus, indicating decreased
intracranial compliance.
A powerful method for estimating CSF dynamic parame-
ters is obtained by mathematical expressions calculated
from the model, together with active infusion of artificial
CSF. CSF infusion patterns can be bolus, constant flow or
constant pressure. One challenge with CSF dynamic meas-
urements is that the infusion rates are small in compari-
son to the often large physiological variations. In some
patients these variations can reduce the reliability of the
determined Rout considerably. The precision of each indi-
vidual Rout measurement should thus be estimated using
all three methods. The infusion test for assessment of CSF
dynamics is used clinically for diagnosing and predicting
the response to shunting and for assessment of shunt
functioning in-vivo.
Aspects of valve and shunt dynamics and 
pathology in hydrocephalus
Pathologic considerations in hydrocephalus. Edward Stopa
During early development, the primitive neural tube
undergoes a complex sequence of differentiation into the
numerous cell types found in the adult brain and spinal
cord. Once completed, the brain is designed to remain in
a steady state throughout the human lifespan. During the
aging process, however, a number of well-recognized
changes begin to occur in the brain. The cerebral ventricles
increase in size due to a combination of brain atrophy and
a degeneration of brain transport interfaces at the level of
the blood-brain (BB) and blood-cerebrospinal fluid (B-
CSF) barriers. These transport interfaces are essential for
maintaining the steady state of the interstitial milieu pro-
vided by the extracellular fluid and CSF that is required for
normal neuronal function. Aging effects on the choroid
plexus and arachnoid granulations lead to a reduction in
CSF production and reabsorption, ultimately resulting in
the accumulation of harmful proteins. CSF dynamics are
very complex and poorly understood. Recent evidence
suggests that there is a communication between the sub-
arachnoid space and the nasal lymphatics, and that this
pathway may be important for normal CSF drainage.
Another area that remains an enigma is syrinx formation
and enlargement in the spinal cord. All these aspects and
the entire complexity of the CSF dynamics throughout life
stages, have to be taken into consideration when trying to
understand and evaluate valve and shunt dynamics and
failure of shunt treatment in hydrocephalus.
Hydrodynamic shunt dysfunction in NPH: known and
unknown risks and how to avoid them. Juan Sahuquillo
Lack of clinical collaboration makes it probable that ran-
domized clinical trials are never conducted in the clinical
treatment of normal pressure hydrocephalus (NPH).
However, a clear trend towards better outcome has been
shown in studies published in the last decade, due in part
to the availability of more sophisticated shunt hardware.
Because there is no robust evidence proving that any valve
is superior, neurosurgeons face important dilemmas in
choosing the most adequate shunt. This step is essential
for improving outcome and avoiding shunt-patient mis-
match, a concept coined in cardiac surgery and easily
extrapolated to hydrocephalus. One known consequence
of hydrodynamic mismatch is shunt over drainage. How-
ever, a lesser known consequence of poor hardware selec-
tion is occult shunt dysfunction that causes lack of
improvement, or initial improvement and later deteriora-
tion. Shunt selection must be based on the fact that both
ICP and CSF dynamics are highly heterogeneous in NPH.
Patients may have active hydrocephalus (mean ICP above
12 mmHg), compensated hydrocephalus (mean ICP 5–
12 mmHg) or even low-pressure hydrocephalus (< 5
mmHg). In patients with active or compensated hydro-
cephalus, we recommend using low or very-low pressure
opening ball-in-cone valves together with gravitationalCerebrospinal Fluid Research 2008, 5:19 http://www.cerebrospinalfluidresearch.com/content/5/1/19
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devices (GD). G-valves alone or adjustable valves plus GD
are alternative options. However, neurosurgeons must be
aware that independent studies show a wide variability in
the opening pressure between manufacturers, and even
between valves of the same manufacturer. In addition,
shunt resistance varies greatly, with some valves not suit-
able for NPH patients. Neurosurgeons should base their
choice on information from both independent studies
and from that provided by manufacturers.
Brain biomarkers and brain metabolism in 
hydrocephalus
Biomarkers for (differential) dementia diagnosis. Peter Paul
De Deyn and Sebastian Engelborghs
As CSF reflects brain metabolism, CSF biomarkers can be
used for unraveling pathophysiological mechanisms and
for diagnostic purposes. To identify neurochemical corre-
lates of neuropsychiatric symptoms, we determined bio-
genic amines and metabolites in CSF by means of HPLC.
In frontotemporal dementia, increased dopaminergic
activity and altered serotonergic modulation of dopamin-
ergic neurotransmission were associated with agitated and
aggressive behavior.
A promising approach to increase diagnostic accuracy is
the use of the CSF biomarkers β-amyloid peptide (Aβ1–42),
tau-protein (tau) and phosphorylated tau (P-tau181P).
Assessing Aβ1–42, T-tau, and P-tau181P in CSF from 200
autopsy-confirmed dementia and control subjects, new
models have been developed, enabling the use of the dif-
ferent biomarkers in optimal algorithms defined by the
clinical need. The models showed promising sensitivity,
specificity and diagnostic accuracy levels systematically
exceeding 80%. Biomarker-based diagnostic models can
as well be applied in diagnostically doubtful cases. More-
over, these biomarkers have a predictive value for conver-
sion to dementia in mild cognitive impairment. In the
light of future biomarker applications such as monitoring
of disease progression, the concept of in vivo surrogate
biomarkers should be further explored in order to under-
stand the relationship between circulating biomarkers
and pathological mechanisms in the brain.
CSF biomarkers for chronic adult hydrocephalus: advances and
challenges. Conrad E. Johanson
CSF signal analysis holds considerable promise for more
precise diagnosis and management of neurodegeneration.
Source, sensitivity and staging are key factors in clinically
advancing CSF biomarker utility. Brain, choroid plexus
and plasma need to be distinguished as potential sources
of CSF proteins and peptides, including amyloid-beta
fragments. Augmented permeability (in advanced degen-
eration) of both the blood-CSF and blood-brain barriers
affect marker concentration in CSF. The use of 2D chro-
matography corrects for the 'swamping' effect of plasma
proteins in CSF samples, thereby improving chances of
detecting low (but potentially significant) levels of novel
biomarkers secreted by choroid plexus and glia (homeo-
static response involving immune and stabilizing factors)
or catabolites released by disintegrating neurons in dis-
ease-affected regions. Combination or ratio analyses of
amyloid/tau derivatives in CSF have become increasingly
useful as specific indicators of neurodegenerative stage.
Longitudinal studies of the CSF composition during pro-
gressive aging will promote better interpretation of NPH
stages and improve differential diagnosis with CSF bio-
chemistry in Alzheimer's (AD) versus  other types of
dementia. Comprehensive banking of simultaneously
procured CSF and plasma samples for aging/NPH/AD, in
conjunction with refinements for brain/CSF image
biomarking, should provide the requisite information for
delineating neurodegeneration and enhancing the CNS
response to various therapeutic modalities.
Classification, etiology and co-morbidity of 
hydrocephalus
Toward a definition and classification of hydrocephalus: Why
it is important. Harold L. Rekate 
There is no agreement as to the definition of hydrocepha-
lus, the subject of this entire conference. The currently
accepted classification of hydrocephalus was proposed in
1919. Understanding of the condition and development
of tools to study the problem have exploded, especially
since the development of contemporary neuroimaging. It
is essential to develop a consensus on these issues in light
of these new discoveries, in order that researchers in
diverse fields may develop understanding of the implica-
tions and importance of the research efforts of others. A
new classification would provide structure to plan and
assess ongoing and planned research.
Proposed definition: Hydrocephalus is an active disten-
sion of the ventricular system of the brain from the point
of CSF production within those ventricles to the point of
absorption into the systemic circulation. Proposed classi-
fication as modified by the discussion:
A. Hydrocephalus secondary to points of obstruction
1. Foramen of Monro
2. Aqueduct of Sylvius
3. Outlet foramina of the fourth ventricle
4. Obstruction of the basal cisternsCerebrospinal Fluid Research 2008, 5:19 http://www.cerebrospinalfluidresearch.com/content/5/1/19
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5. Obstruction of distal CSF absorption
6. Intracranial venous hypertension
B. Hydrocephalus without obstruction
1. Choroid Plexus Papilloma
2. Are there any other examples?
The new International Society for Hydrocephalus and CSF
Disorders launched at Hydrocephalus 2008 should com-
mit itself to the development of a consensus on these
issues.
Experimental hydrocephalus
Experimental hydrocephalus: animal models past and present.
Hazel C. Jones
Treatment for hydrocephalus is usually based on some
type of surgical intervention. Advances in shunt technol-
ogy, in imaging and in monitoring techniques, have
brought improvements in patient management. Animal
models for hydrocephalus have and will continue to have
a role in this progress. Specifically, the experimental con-
ditions can be varied to suit the objectives and can be used
to test hypotheses. Brain and CSF pathology can be stud-
ied before and after shunt treatment.
Four categories of animal model are: CSF obstruction (any
age), induction with teratogens (fetal or neonatal), viral
infections (neonatal), and genetic (any age, usually fetal
or neonatal). Ventricular dilatation is variable depending
on method but is generally more severe in young animals.
Most models with shunt treatment show partial recovery
but some changes are irreversible, particularly in the
periventricular white matter.
The numerous teratogenic chemicals that disrupt brain
formation, demonstrate that the developing brain is
highly sensitive to adverse influences. In these circum-
stances dilated ventricles can occur without CSF obstruc-
tion. Genetic hydrocephalus can arise naturally or be
caused by genetic manipulation. Improved knowledge of
the genes involved in hydrocephalus is providing infor-
mation that can be used to investigate unexplained fetal
hydrocephalus in humans. In summary, animal models
are essential to improve understanding of human hydro-
cephalus.
Correspondence between animal models and pathology in
human hydrocephalus Marc Del Bigio. 
Correlations between human disease states and experi-
mental animal models are possible. However, one must
always remember the caveats. The basic properties of indi-
vidual brain cells and their components are similar across
mammalian species, but subtle differences exist with
respect to molecular and genetic composition. At the
organ level, the major components and connections are
similar but the ratios differ; non-gyrencephalic animals
have less frontal lobe volume and far less white matter.
The degree of brain maturity at birth differs widely across
mammalian species, and smaller animals mature faster.
For hydrocephalus and other neurological disorders one
can and should compare behaviour (motor and cogni-
tive), imaging, CSF composition, tissue (histology and
biochemistry), and response to drug therapy. Many mod-
els of hydrocephalus are available. The initiating factors
reflect on human states with varying degrees of fidelity.
For example, the blood injection model has strong simi-
larity to post hemorrhagic hydrocephalus. The kaolin,
fibroblast growth factor, and transforming growth factor
models mimic to some extent the meningeal inflamma-
tion and/or fibrosis that occurs after meningitis or hemor-
rhage (including trauma). Silicone oil, cyanoacrylate
glues, and other synthetic polymers effectively obstruct
CSF flow in a totally artificial manner. The genetic models
(H-Tx rat, L1CAM mouse, ciliary dyskinesia, and others)
are useful for various aspects of hereditary and fetal onset
hydrocephalus. As in humans, the animal models of
hydrocephalus develop head enlargement, motor and
cognitive changes, periventricular white matter damage,
and they respond to shunting. One can therefore conclude
that the animal models of hydrocephalus mimic human
pathology to a high degree. However, the experimenter
must know the limitations of the model as well as details
of the comparative development and neurobiology.
Treatment of hydrocephalus and management 
of complications
Important aspects of complications in shunt surgery. Bertil
Romner
Shunt surgery, is the most common treatment for both
paediatric and adult normal pressure hydrocephalus
(NPH). The most frequent complications of shunt surgery
are: over- and under drainage and infections. Over drain-
age presents as symptomatic subdural hygromas, hae-
matomas and slit ventricles. Under drainage is either
related to obstruction, disconnection, malpositioning, or
migration of the shunt system or to a valve with, or set at,
excessively high opening pressure, leading to functional
under drainage. Less frequent complications related to the
surgical procedure are intracranial bleeding or pneumato-
cephalus, and in the case of adjustable valves, the likeli-
hood for accidental readjustment. The type and rates of
complications differ for paediatric and adult hydrocepha-
lus. During the first year after shunt surgery in paediatric
hydrocephalus, 10–20% have a shunt infection and aboutCerebrospinal Fluid Research 2008, 5:19 http://www.cerebrospinalfluidresearch.com/content/5/1/19
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17% have shunt malfunction. In adult hydrocephalus, the
complication rates for surgery are: infection 5–10%,
mechanical malfunction 10–30%, and subdural hae-
matoma, 10–15%. In NPH, these complications are rated
severe in 20% of patients. Less frequent, but important
complications are epilepsy 1–7%, and hearing or visual
failure each 2%.
Shunts with adjustable valves enable the functioning pres-
sure to be modified in situ and allow non-invasive man-
agement of complications such as over drainage and slit
ventricles, and under drainage. Adjustments are not
always associated with improvement and the manage-
ment of non-responders needs to be handled more rigor-
ously: patients without clinical improvement in the
presence of unchanged ventricular width in spite of sev-
eral valve adjustments, need a shunt function test fol-
lowed by a shunt revision if the result is equivocal or
positive. To date, these are either radio- nuclide studies or
lumbar infusion tests. The lumbar constant rate infusion
test allows assessment of the actual valve opening pressure
and comparison with preoperative measures: a decrease in
resistance to outflow indicates improved dynamic status
and a working shunt.
One problem with adjustable valves is that they can
become re-set accidentally with magnetic fields, as in MRI,
cell phones, headphones and home magnets. For the
Hakim-Medos valve, 140 patients undergoing MRI
resulted in a valve setting change in 35 (25%). Questions
still to be resolved are whether the following situations
affect revision rate in individual patients: using a uni-
shunt (to avoid disconnections), endoscopic or navigated
placement of ventricular catheters, peritoneal versus atrial
placement of the distal catheter, the site of the ventricular
catheter (occipital versus frontal) and the use of adjustable
valves.
Infection as a major complication in shunting and external
drainage: Roger Bayston
Among the complications of cerebrospinal fluid shunting
and intracranial pressure management by external ven-
tricular drainage (EVD), infection is one of the most seri-
ous. The incidence varies, both in the literature and in
clinical experience. Figures cited for shunting are around
5% for adults but three to four times higher in infants less
than six months old. The infection rate for EVD is more
difficult to determine because of the different case defini-
tions for diagnosis. However, in most centres it is at least
10% when the diagnosis includes ventriculitis. The clini-
cal consequences of ventriculitis include deterioration in
cognition, which can result in decline in quality of life so
that the patient becomes ineducable, unemployable and
profoundly dependent. In ventriculoperitoneal shunts,
infection often causes obstruction of the distal catheter
and in some cases loss of absorptive capacity in the peri-
toneal cavity, requiring alternative routing of the shunt. In
both shunting and EVD most infections are caused by sta-
phylococci, but gram negative bacteria are also important,
especially in EVD, and for the patient on the intensive care
unit multi – resistant Acinetobacter baumanni is a problem.
Propionibacterium acnes is an under-detected cause of
shunt infection. Despite many studies of varying scientific
validity, there is still no clear evidence that perioperative
prophylactic antibiotics reduce the infection rate, and in
EVD they have been found to increase the proportion of
resistant gram negative infections. Antimicrobial catheters
have shown benefit in both shunting and EVD, though
the role of silver-processed catheters remains undeter-
mined. Treatment of infection should include catheter
removal, preferably with intraventricular antibiotics,
although linezolid has been found to give high CSF levels
after oral administration, and promises to be useful for
staphylococcal infection. For Acinetobacter EVD infections,
intraventricular colistin is safer then intravenous. Risk of
infection can be reduced by shorter pre-operative hospital
stay, less use of antibiotics with, where possible, shorter
courses, locally targeted antibiotics (intraventricular
route, antimicrobial catheters), and enhanced state spend-
ing on health care.
Endoscopic third ventriculostomy and 
management of hydrocephalus
Endoscopic third ventriculostomy: evolution of indications and
technique Michelangelo Gangemi.
Endoscopic third ventriculostomy (ETV) is a surgical pro-
cedure that allows the CSF to flow directly from the third
ventricle to the basal cisterns and subarachnoid spaces,
thus by-passing the aqueduct and the CSF pathways of the
posterior fossa; its indications and the interpretation of its
significance in different forms of hydrocephalus have
changed since the introduction of this technique into neu-
rosurgical practice over the last twenty years.
While earlier understanding considered ETV as a simple
internal shunt which created a CSF diversion requiring
patent subarachnoid spaces and adequate resorption to
ensure benefit to the patient, recent successful applica-
tions in forms of so-called non-obstructive hydrocephalus
(i.e. post- infection and hemorrhage), demand new inter-
pretations for the mechanisms by which this procedure
works. Restoration of brain pulsatility and physiological
CSF dynamics may play an important role in the positive
effects of ETV, other than just CSF diversion. Nowadays,
despite great technological improvements in the construc-
tion of endoscopic devices and a well-established surgical
technique, many points still remain controversial and
debated, like the usefulness of ETV in other pathologicalCerebrospinal Fluid Research 2008, 5:19 http://www.cerebrospinalfluidresearch.com/content/5/1/19
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entities such as 'normal pressure' hydrocephalus in old
age and hydrocephalus of newborns.
Endoscopic third ventriculostomy: outcome, controversies and
future perspectives. Joachim K. Krauss
Endoscopic third ventriculostomy (ETV) has been estab-
lished as a safe treatment for obstructive hydrocephalus in
selected patients, with fewer overall complications than
shunt insertion. The most common problems for ETV are
poor intraoperative vision because of technique (blood
leaks), CSF leaks, subdural fluid collection, ventriculitis or
meningitis. Some patients fail to improve and a range of
studies has demonstrated variable success rates of 50–
90%. In addition, there are many serious, but less com-
mon complications such as herniation, arrhythmia, injury
to brain structures especially important structures in the
third ventricle, haemorrhage, ischaemic stroke, and infec-
tions. Of upmost concern is sudden death, which may
occur in acute as well as in the later follow-up stages, e.g.
late death after sudden closure of stoma after successful
procedure.
Repeated ETV procedures have higher complication rates
than the first intervention (55.5% versus  10%). Unre-
solved controversies are the use of ETV in infants <2 years
old, in NPH patients, and in previously shunted patients
with obstructive hydrocephalus. In infants less than 2
years, the success rate has been low, although recently a
small study reported 57% success. In NPH a 69%
improvement rate has been reported. Clearly success is
dependent on the presence of a patent subarachnoid
space. Previously shunted patients have been treated with
ETV after shunt malfunction, and a proportion (38–84%)
become shunt free as a result, with variable complication
rates. Complications are more frequent than in patients
with newly diagnosed hydrocephalus, according to a ret-
rospective review of 131 shunted and un-shunted patients
from various age groups and with various etiologies
treated with ETV. Shunt-related over drainage can be suc-
cessfully treated with ETV followed by removal of the
shunt. Nowadays, the long-held dogma 'once a shunt –
always a shunt' is definitely no longer valid.
Outcome in hydrocephalus and CSF Disorders
Outcome in hydrocephalus and CSF disorders. Mark Luciano
The chairs' lectures introduced the problems of outcome
analysis in hydrocephalus. Domenico D'Avello from
Padova discussed data collection stressing the importance
of multi- institutional collaborative registries, such as
developed in Italy, to gather more accurate outcome data.
The subjective nature of chronic hydrocephalus symp-
toms and the need to use quantitative measures,
restrained interpretation and controls was stressed by
Mark Luciano who called for a randomized placebo-con-
trolled crossover NPH outcome study to better evaluate
subjective response.
In this session, four subsequent speakers discussed the
prediction of outcome in NPH. C. Sprung from Berlin
compared outcome with an adjustable system to their
own fixed pressure historical controls and described fewer
revisions caused by drainage issues. J. Lemcke, from Berlin
proposed that a gradual reduction of CSF opening pres-
sure over the first six months of treatment may reduce
over drainage symptoms. M. Schuhmann related trial CSF
drainage outcome with measurements of CSF reserve
capacity, pressure-volume index and elasticity. In addi-
tion, they showed the greatest improvement at the one
month time point after shunting. On the other hand, N.
Chautouras from Greece reported a 95% improvement
rate using only imaging and an ICP measurement for NPH
patient selection. A serious complication, Dorsal Mid-
brain Syndrome, was described by M. Kiefer resulting
from over-shunting in obstructive hydrocephalus causing
possible midbrain injury. This syndrome requires both
surgical procedures, to reduce drainage, and symptomatic
medical treatment. V.M. Gerganov reviewed hydrocepha-
lus associated with vestibular schwannomas, describing a
correlation between the degree of hydrocephalus and size
of tumor. However, predicting the need for direct treat-
ment of the hydrocephalus was difficult.
Other CSF disorders, benign intracranial hypertension
(BIH) and cerebral cysts were discussed by A. Tarnaris and
T. Keinert, respectively. BIH remains a difficult disorder to
treat with a 72% and 48% reduction in headaches and vis-
ual disturbance, respectively and a 34% shunt revision
rate. T. Keinart, from Heidelberg described a valveless cyst
ventricular shunt for the treatment of cerebral arachnoid
cysts in a series of 6 patients. A sense of the complexity of
outcomes in CSF disorders and difficulties in generalizing
from small series without controls, pervaded and enlight-
ened the session's discussion.
The Italian multicenter web-based iNPH study. Analysis of
shunt-related complications. Domenico d'Avella (on behalf
of the Italian NPH group of the SINch, Padova, Italy)
A multicenter prospective controlled study was performed
for the diagnosis, treatment, and analysis of long-term
outcomes in normal pressure hydrocephalus (NPH). The
aim of this report was to describe the rate of complica-
tions, morbidity, and mortality associated with shunts at
the time of the operation and after the surgical procedure.
A total of 143 patients were enrolled, of whom 140 com-
pleted their follow-up. Patients were implanted a Cod-
man Hakim programmable shunt valve. Enrolment wasCerebrospinal Fluid Research 2008, 5:19 http://www.cerebrospinalfluidresearch.com/content/5/1/19
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based on the criteria of the Italian Study Group of NPH.
Median follow-up for the study was 24 months. Perioper-
ative mortality rate was 2.1%, due to pulmonary embo-
lism. Total complication rate was 10.7%, requiring
additional surgeries in 7.1%. Total intra-operative compli-
cations were 2.8%, and late infection-related shunt mal-
functions occurred in 5.7%. We recorded 2.1% of
subdural fluid collections, being surgically evacuated in
one case and treated with valve pressure readjustment in
two cases. Valve opening pressure re-adjustments were
necessary in 35% of patients. The increased knowledge of
the topic, the modern standard of care of patients, the
application of rigid inclusion criteria for selecting appro-
priate shunt candidates, and the availability of program-
mable valves, make shunt surgery in NPH patient a safer
procedure, as compared to previous data in the literature.
Technical advances in surgical management of 
hydrocephalus
Finding the right treatment. Magnus Tisell
Technical advances include any innovation which
improves the management of the hydrocephalus patient
and ideally also the outcome. We could either improve
the shunts or make the patients shunt-independent. Fac-
tors that can improve shunt surgery are changes valve
design, antisiphoning devices, different shunt materials
and different design and position of catheters and tubes.
The most obvious strategy for shunt-independency is
removing an underlying cause such as an obstructive
intracranial lesion. An unnecessary shunt should be
avoided by improving the criteria for surgery. The most
common endoscopic procedures for achieving shunt-
independency are ventriculocisternomy and fenestration
of cysts. In the future there will probably be effective drug
therapies. Many inventions are focused on reducing com-
plications and side effects. Equally important is functional
status after optimal treatment. Any new treatment has to
be tested against current standards. The placebo effect is
well known, but there are also the negative nocebo effects.
Long term effects are by definition unknown when a new
device is introduced and are particularly important in life-
long diseases such as hydrocephalus. In summary, what
we look for are long lasting inventions with clear indica-
tion(s), few complications, few side effects, and optimal
functional outcome. To achieve this, we need excellent
clinical science.
Validation of technical advances in the treatment of hydroceph-
alus. Gerald D. Silverberg
New shunt devices and techniques are reported regularly.
The benchmark for evaluating clinical devices and tech-
niques is the prospective, randomized double-blinded,
placebo-controlled trial. There are pitfalls inherent in
designing a well-controlled trial, as exemplified in our
trial of low-flow CSF shunting in Alzheimer's disease
(AD). We compared a functioning shunt group to an
occluded shunt group using a novel, low-flow V-P shunt
system. We chose two FDA-approved end-points: the Mat-
tis Dementia Rating Scale (MDRS), and the Global Dete-
rioration Scale (GDS). The generalized estimating
equation (GEE) compared the two randomized groups.
The study was halted when the GDS did not change over
nine months in either group. Several retrospective flaws
were identified: 1) the GDS was too insensitive. A second-
ary activities of daily living measure (ADCS-ADL) showed
a benefit, 2) there were too many moderate-severe AD
subjects (>30%). We intended to treat only early AD, 3)
the shunts used did not perform reliably in situ, and 4) the
statistical method used was ill-suited to the wide variation
in responses in the test group. In two post hoc analyses
using a linear mixed effects statistical model, the MDRS
and the ADCS-ADL as end-points, there was significant
benefit of active shunting in early AD, (MDRS p = 0.028,
ADCS-ADL p = 0.021)
Epidemiology, trials and registries
The Swedish longitudinal adult hydrocephalus surgery registry:
Kristina Cesarini
In 2004 all six University Hospitals in Sweden started a
quality registry that provides online data access of the
unit's own hydrocephalus figures and the national figures
for comparison. All adults = 18 years that underwent first
time surgery (shunt and 3rd ventriculostomy) for hydro-
cephalus are included. The web-based registry is con-
nected online to the national population register that is
automatically updated for geographical data and deaths.
Hydrocephalus is classified as communicating/non com-
municating, idiopathic/secondary. Basic demographic
data, baseline diagnostic work-up, coexisting diseases and
neurological function are registered with validated scales
according to a standardised protocol. Main surgical and
technical details, complications, reoperations and shunt
adjustments are also registered. Follow up function is
evaluated at 3 and 12 months postoperatively. Up to Sep-
tember 2008, 1018 patients, 50% females, age 18–88)
were registered.
Eighty-two percent had communicating hydrocephalus,
of which 42% were idiopathic and 32% after SAH. Sixty-
two percent of the obstructive hydrocephalus was second-
ary to tumour. Adjustable valves were used in 79% of all
shunt procedures, third ventriculostomy was performed
in 66% of all obstructive hydrocephalus. Three hundred
and thirty valve adjustments were done and 201 patients
had 269 complications, 92% occurring during the first
year after surgery. CNS infections were found in 4%,
incorrect shunt placement/displacement in 5%, 4% hadCerebrospinal Fluid Research 2008, 5:19 http://www.cerebrospinalfluidresearch.com/content/5/1/19
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CNS/shunt infections and 4% experienced obstruction/
disconnection. Improvement after surgery persisted
through the follow up year. Twenty percent had repeat
surgery due to complications. Serious complications were
rare and postoperative haematomas were <0.5%.
Although delay in registration is still a problem, we have
now a national collaboration and common measure-
ments to evaluate the quality and performance after
hydrocephalus surgery.
Trials, registries and audits – which is best? Hugh K. Richards
All clinical investigations designed to evaluate novel treat-
ments are potentially subject to bias, and it is important
that investigators are aware of both potential sources of
error and key principles of study design, in order to reduce
them. The two most important sources of bias are selec-
tion bias and observer bias which may be substantially
reduced by randomization and blinding respectively. A
randomized, double-blind clinical trial is regarded as pro-
viding the most valued data. However, in the field of
hydrocephalus research, where the subject of the trial is a
procedure or a device, blinding is rarely achievable.
Audits are generally neither randomized nor blind and
may be subject to study management bias. Treatment
groups must be handled equally with regard to all the
study procedures. This is extremely difficult when cases
and controls are studied at different times. However, audit
data is often the first data available and may trigger further
trials.
Registries are not blind and may be subject to manage-
ment bias, but because the dataset under investigation
may be large, (The UK Shunt Registry currently holds data
on over 40,000 procedures) some degree of randomiza-
tion may be achieved by performing matched-pair studies
where controls are randomly selected.
One problem with all investigations is the number of
patients required to achieve significance. A sufficiently
powered study evaluating a comparatively rare event
(such as shunt infection in adults) requires the recruit-
ment of as many as 2,000 patients. This number is
reduced in patients at greater risk but will generally
require several hundred patients. A study involving shunt
revision for causes other than infection will also require
long term follow-up. Because of the lack of perfect inves-
tigations in hydrocephalus, investigators should be aware
of sources of bias and design protocols to minimize them.
Furthermore the requirements of science must always be
balanced with ethical considerations. Finally, reviewers
must be able to evaluate submitted evidence, and not
allow authors to make conclusions that are not justified
by the data.
Pharmaceutical modulation of the CNS (CNS 
drug delivery)
Interstitial delivery for biological agents in brain tumour ther-
apy. Peter M. Black and Rona S. Carroll
Interstitial methods for delivering drugs directly to the
brain for tumor therapy include cannulas attached to min-
ipumps, encapsulated cells, and microparticles. With the
osmotic minipump, a drug solution is infused directly
into the brain via a cannula attached to a subcutaneous
reservoir, using osmotic pressure to provide a constant
delivery rate. This system has been tested in mice with
implanted gliomas. Infusion of murine or human
endostatin results in reduced blood vessel density,
reduced proliferation and increased apoptosis. Cell
encapsulation uses implanted genetically engineered cells
that secrete a therapeutic protein and are encapsulated in
an immunoisolating material (alginate and poly L-
lysine). The advantages of this method are that there is
minimally invasive surgery, the cells constitutively pro-
duce protein and the capsules are biocompatible. Disad-
vantages are that long term cell viability may be poor and
the rate of output may be erratic. Polymeric microspheres
are prepared from a polymer and emulsifier with thera-
peutic compounds trapped inside. They release the drug
continuously over time. Microspheres containing the
platelet derived growth factor (PDGF) inhibitor, Gleevec,
when implanted into mice with gliomas significantly
reduce the size of the tumour and increase apoptosis. It is
concluded that local delivery to the brain increases the
efficacy of therapeutic agents.
Drug delivery to the brain via the CSF system – perspectives
and limitations. Thomas Brinker
Recent understanding of the molecular pathways in both
acute and chronic brain disease has raised the need for
efficient drug delivery to the brain, to enable direct inter-
ventions in pathological cascades. Different routes have
been used: intravascular or local intracerebral application.
The intravascular route is limited by the blood brain bar-
rier (BBB), particularly for non-lipophilic substances, but
also for most lipophilic agents larger than 500–600 Da.
Since modern potential therapeutic agents are either small
oligonucleotides and peptides or more complex lipo-pro-
teins (antibodies), penetration through the BBB is essen-
tially nil. Therefore, methods for local intracerebral drug
delivery have been pursued in the recent past. Using sub-
stances injected or infused into the CSF space, it was dem-
onstrated that the entire brain tissue may be
pharmacologically targeted. However, despite the poten-
tial for continuous delivery, the effects can be suboptimal
because of non-selective receptor activation, and subther-
apeutic concentrations because of enzymatic degradation,
ependymal receptor binding and/or rapid CSF clearance.Cerebrospinal Fluid Research 2008, 5:19 http://www.cerebrospinalfluidresearch.com/content/5/1/19
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The use of genetically engineered cells, which continu-
ously release substances, i.e. neuropeptides, has been
investigated recently in the clinical and experimental set-
ting. Here, genetically engineered human mesenchymal
stem cells (hMSCs) provide a promising vehicle, as they
are non-embryonic, non-tumorigenic, and non-prolifera-
tive. Furthermore, encapsulation of those cells in alginate,
a biocompatible biopolymer, allows 'immunoisolation'
preventing allogenic host-versus-graft reactions, and also
allows osmotic passage of nutrients and therapeutic
agents. We locally implanted genetically engineered algi-
nate encapsulated hMSCs releasing the neuroprotective
peptide Glucagon-like peptide-1 (GLP-1) in experimental
traumatic brain injury, and were able to demonstrate sig-
nificant reduction of hippocampal neuronal loss in the
stem-cell treated animals. When it comes to the human
application, retrievability of cells is an important safety
issue, and we have developed a prototype device for
intrathecal implantation of those cells, which is now used
in a phase I/II trial in patients with hemorrhagic stroke. It
is thereby hoped to improve encapsulated cell biodeliv-
ery, also called ex-vivo gene therapy, to exploit the CSF sys-
tem for pharmacological manipulation of the nervous
system.
Cognition in hydrocephalus and related 
dementias
The neuropsychology of normal pressure hydrocephalus, estab-
lished facts and remaining problems. Per Hellström
Memory impairment, and cognitive deterioration, albeit
imprecise and far from synonymous, point to the fact that
patients with NPH, in general, undergo mental changes.
The cognitive deficits and behavioural manifestations of
NPH are often said to indicate or, at least resemble, frontal
dysfunction. However, a search of the literature from the
mid seventies until the present, gives a picture of more
widely distributed pathological changes. Affected neu-
ropsychological and cognitive functions include: abstract
thought, apprehension, attention, numeracy, concentra-
tion, dexterity, executive function, higher integrative func-
tions, orientation, manipulo-spatial, motor perception,
pragmatic language, psychomotor speed, short term
memory, verbal language, visual construction and percep-
tion, working memory, and writing skills. Reported
numerous behavioural and psychiatric changes include:
aggression, altered consciousness, apathy, aspontaneity,
awakening fluctuations, bradyphrenia, depression, dis-
turbed impulse control, easily fatigued, emotional distur-
bance, fantastic confabulation, apraxia, impaired
wakefulness, indifference, inertness, bipolar disorder,
negative frontal syndrome, obsessive compulsive disor-
der, obtunding, perseveration, positive frontal syndrome,
psychosis, and reduced alertness.
Acknowledging the fact that NPH can affect most neu-
ropsychological areas, investigators now need to agree on
the selection of a few instruments, capable of reflecting
some of the most conspicuous changes. These instru-
ments will have to be proven to be reliable (resisting prac-
tice effects), validated (ideally, strongly associated with
physiological measures), sensitive (discriminative) and
able to detect changes following treatment.
What can we learn from cognitive neuroscience for hydroceph-
alus diagnosis? Thomas Münte
Cognitive neuroscience has a classical tradition based on
localisation, the isolation of single cognitive processes,
and the technique of minimal contrasts. However, the
clinical neurologist needs to know the functional changes
in the whole brain network. There are two possibilities for
the whole brain approach: functional magnetic resonance
imaging (fMRI) that has been used for multiple sclerosis
patients, and independent component analysis (ICA)-
based definition of resting state networks used in amyo-
trophic lateral sclerosis (ALS) and dystonia patients.
A method that could be applied to normal pressure hydro-
cephalus is fMRI plus global cognitive stimulation
(GLOSTIM). For this test, a task is performed that taxes
many cognitive processes and is combined with fMRI
imaging. This gives a picture of diffuse global activation
that could be used as an index of destruction and compen-
sation.
The ICA-based method assumes that brain areas are con-
nected to functional networks with neurophysiological
activity. The activity is reflected in the fMRI blood oxygen
level dependent (BOLD) signal which can be measured
during task execution and at rest. ICA analysis is used use
to extract the activity due to spatially and temporally inde-
pendent networks from the spontaneous fluctuations in
the BOLD response. The advantages of this method for
use in hydrocephalus clinical research are that it is easy to
perform in most MR scanners with a run time of 6 min on
scanners of 1.5 T or more, does not require any specific
equipment, it is not task biased, shows sensitivity to
change and has shown a high inter-individual stability.
Quality of life, social impact, health care and 
rehabilitation
Quality of Life: What does it mean to patients and families?
Dory Kranz
From my perspective as a patient advocate, not a scientist,
I see that quality of life is highly important to people with
hydrocephalus and means essentially the same to them as
to any human. In a survey of Hydrocephalus Association
community members, overall quality of life was rated # 1Cerebrospinal Fluid Research 2008, 5:19 http://www.cerebrospinalfluidresearch.com/content/5/1/19
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in importance by almost a 20% margin. Quality-of-life
markers like education, employment and relationships
were three of the next five priorities – ranked in impor-
tance between the critical medical issues of shunt mal-
function and shunt infection. Dr. Abraham Maslow's
hierarchy of needs provides a framework in which people
seek successively higher level needs as the more basic
needs are met. The advent of shunting and extraventricu-
lar drain as treatments, resolved – for the most part – the
most basic physiological needs and allowed people with
hydrocephalus to stay alive. Research focus then moved to
the next level of needs which includes health safety. When
individuals with hydrocephalus are not in a life-threaten-
ing emergency due to shunt malfunction, infection or
some other complication, they seek the next higher level
needs of love/belonging (friendship and love relation-
ships), esteem (education and employment) and self
actualization. Traditionally, little time has been spent
looking at these higher level outcomes scientifically. Some
exciting research is beginning to address quality of life:
paediatric outcomes research and questionnaire by
Abhaya Kulkarni and colleagues at the University of
Toronto; cognitive outcome research by David Frim and
Maureen Lacy at the University of Chicago; and work by
Nalin Gupta and associates at UCSF, to understand long
term outcomes for adults treated in childhood.
Quality of Life: What does it mean? How do we measure it?
How can it influence clinical care and research? Michael A.
Williams
The outcomes usually measured in adult or paediatric
hydrocephalus (e.g. gait, balance, neuropsychological
function, continence, headache) are scientific outcomes
and not quality of life outcomes. Health-related quality of
life is defined as 'the degree to which persons perceive
themselves able to function physically, emotionally, and
socially'. Health Status is 'the degree to which a person is
able to function physically, emotionally, socially with or
without aid from the health care system'. The best body of
work in health status measurement in hydrocephalus is by
Abhaya V. Kulkarni at the Toronto Hospital for Sick Chil-
dren. The 51-item Hydrocephalus Outcome Question-
naire (HOQ), administered to parents of children with
hydrocephalus, has been carefully designed and validated,
and provides an overall score plus sub scores for physical
health, social-emotional health, and cognitive health.
Variables resulting in lower HOQ scores include seizures
and multiple shunt revisions. The mean utility score (a
method that allows meaningful comparison between dif-
ferent health status measures) with the HOQ is 0.77,
which compares to 0.87 for teenagers born with extremely
low birth weight, or 0.85 for paediatric survivors of Hodg-
kin disease. Quality of life instruments allow hydroceph-
alus to be compared with other disorders, and can be
paired with health expenditure information for cost utility
analysis.
Paediatric hydrocephalus and adolescence
Challenges in understanding and dealing with paediatric
hydrocephalus. Marianne Juhler
Paediatric hydrocephalus has been categorised as either
obstructive or communicating, the former being treated
with endoscopic third ventriculostomy (ETV) and the lat-
ter by shunt surgery. However, particularly some contra-
dictory observations in paediatric patients have
challenged this traditional view. For example, ETV is
sometimes successful in communicating hydrocephalus,
although the success rate is lower in infants. Furthermore,
symptoms of some congenital conditions may present at
later stages of life, for example as LOVA or arachnoidal
cysts. The concept of communicating versus obstructive
hydrocephalus has been challenged. This suggests that the
variable sites for obstruction to flow may be important for
treatment, and that there could be a number of parallel
flow routes. Here, the role of sub- or microstructural water
transport mechanisms at the molecular level is still
unclear: how they relate and add to the known ways of
CSF absorption and to our current biomechanical under-
standing of hydrocephalus. These molecular flow routes
could be genetically determined and also age-dependent.
In the future, treatment paradigms for paediatric hydro-
cephalus could be modified and improved when more
detailed knowledge of the CSF flow routes is forthcoming.
Paediatric hydrocephalus: a survey and some thoughts with
regard to improve treatment. Regina Eymann
In recent time, attempts to understand pathophysiology
of hydrocephalus developed from a mechanical concept
into a concept focusing on compliance. With the help of
dynamic infusion tests, pulse wave analysis, pulsatile
hydrodynamics we try to get another understanding of the
pathophysiology of hydrocephalus. But the disease pat-
tern, especially in children, is not entirely understood.
Nevertheless we implant shunts and perform external
ventricular drains (ETV). There are three major complica-
tions in shunt therapy: over drainage, shunt infections
and foreign body reaction to the silicone catheters. Prob-
lems with complications are:
1. To this day there is no clear definition of the phenom-
enon over drainage.
2. Shunt infection is not clearly defined, and there is no
consensus about the therapy.
3. Foreign body reaction against silicone: it was possible
to mimic this in an animal model.Cerebrospinal Fluid Research 2008, 5:19 http://www.cerebrospinalfluidresearch.com/content/5/1/19
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Is the ETV really the solution for these problems or do we
provoke longstanding overt ventriculomegaly (LOVA)?
Up to now we have no instrument to monitor ICP online
telemetrically in individual patients.
Conclusion
Conference Summary. Anthony Marmarou
Almost half of the contributions to Hydrocephalus 2008
reported clinical studies of which 17% were paediatric;
the other half mostly consisted of laboratory and techni-
cal contributions, showing that hydrocephalus embraces
multi- and trans-disciplinary research. The conference
also supported translational aspects of hydrocephalus
research. Hydrocephalus research has made gains in the
field of advanced imaging techniques, genetic and stem
cell therapies, CSF biomarkers, A-beta clearance and in
disease modelling. However, the search for adequate and
more natural experimental models needs to continue. In
the clinical setting, it appears that there is a greater appre-
ciation for diagnostic accuracy of idiopathic normal pres-
sure hydrocephalus (iNPH), and the use of
supplementary tests has increased in accordance with the
guidelines. In general, non-invasive technology has made
significant advances and progress, e.g. bold signal imag-
ing, magnetic resonance spectroscopy, and diffusion ten-
sor imaging. Mathematical modelling has progressed in
teasing out both compliance and outflow resistance from
volume, flow and pulsatility in the ventricles and in the
subarachnoid space, in pulsatility theory and in the aque-
ductal flow. Furthermore, valve design and technical
equipment are improving, allowing selection for the indi-
vidual clinical situation and for more reliable and practi-
cal assessment of shunt function. We are approaching a >
90% favourable outcome of shunt treatment with a low
frequency of complications. Experience in endoscopic
third ventriculostomy (ETV) has increased from the classi-
cal indications to secondary and idiopathic NPH.
Unfortunately, the low number of patients in many clini-
cal studies makes it difficult to arrive at sound conclusions
and the need for prospective multicenter studies and col-
laboration among centres and investigators needs to be
stressed. Among the 74 clinical papers presented, there
were only 2 concerning prospective randomized trials, 5
prospective controlled trials (4 Shunt related) and only 1
potentially eligible for Class 1 trial. Paediatric studies were
in the minority and a better balance is needed. The big
question is, why, despite accurate diagnosis and state of
the art management, there are still patients that do not
improve. Are these failures refractory to treatment or just
beyond the window of opportunity? The exclusiveness of
shunt treatment, e.g. in NPH, needs a placebo trial for the
effect of shunts or a prospective randomized double-blind
multicenter trial: shunt versus ETV in patients eligible for
either procedure. As further vignettes of the conference,
neuropsychology, cognitive assessment and functional
neuroimaging provided promising and relevant measures
of the disease, as well as differential diagnosis and assess-
ment of outcome after treatment. Epidemiological risk
factors for hydrocephalus do exist; however, race does not
appear to be important. Proteomic analysis of CSF can dif-
ferentiate between iNPH and Alzheimer's disease (AD).
The headline news was that Binswanger's and AD, alone
or coexisting with iNPH, do not preclude a shunt. As one
example, the post hoc analysis of a clinical trial for shunt-
ing of early AD patients using a different global measure,
the Alzheimer's Disease Cooperative Study-Activities of
Daily Living Inventory (ADCS-ADL) showed benefit to
the test group. Furthermore, new approaches for CSF drug
delivery (ex-vivo) and gene therapy are available and have
shown protection against neurotoxins in experimental
studies. Adjunct neuromodulative or neurorestorative
treatment in the human disease is anxiously awaited.
One hopeful sign is that the number of young investiga-
tors has increased. Support is needed to create an environ-
ment that encourages research and facilitates publication
to expand the literature and increase awareness of the dis-
ease. This can only be done by collaborative effort among
researchers and professionals from various disciplines and
allied health professionals, all with a common language.
This needs a platform, and as a further outcome of this
meeting, the newly created International Society of
Hydrocephalus and CSF Disorders (ISHCSF) was inaugu-
rated. As such, task forces are required as soon as possible
for Nomenclature, Classification, Consensus on Outcome
Scales and Quality of Life measures, Standardized Disease
Assessment, Imaging and Reporting of Complications.
Bearing in mind that hydrocephalus is one of the more
complex injuries to the most complex organ, why should
we expect a simple solution? We simply have to keep try-
ing.
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